Impact of Botulinum Toxin injection on Improving Facial Symmetry and Quality of Life in Patients with Long-Standing Peripheral Facial Palsy
Main Article Content
Abstract
Background: Facial palsy can cause significant psychological and social challenges, severely affecting quality of life. Botulinum toxin (BoNT) injection is an effective treatment for persistent facial palsy, enhancing facial symmetry, and alleviating issues such as involuntary muscle movements and tightness.
Objective: This study aimed to evaluate how patients with long-standing facial palsy experienced changes in their quality of life before, one month after, and four months after receiving botulinum toxin (BoNT) injections using three specific questionnaires: HFS-30, FaCE, and HAD. Additionally, the study sought to identify clinical factors linked to improvements in quality of life and assess the applicability of the HFS-30 questionnaire to patients with unilateral facial palsy.
Methods: The study included 88 patients with long-standing unilateral facial palsy. Data were collected on demographics, medical history, facial palsy history, and botulinum toxin injection details. Quality of life was assessed using the HFS-30, FaCE, and HAD questionnaires before the injection, and at one and four months post-injection. Statistical analyses were performed using paired Student’s t-test, Pearson’s correlation coefficient, and linear regression models. Ethical approval was obtained from the IRB (approval number 20211130113517), and all participants provided informed consent.
Results: Eighty-eight patients participated, with 63 women (72%) and 25 men (28%), averaging 53 years old (SD 15.8). Significant improvements in quality of life were observed one month post-injection, with the HFS-30 score improving from 45.1 (SD 22) to 35.4 (SD 20.5) (p < 0.0001) and the FaCE score improving from 50.2 (SD 24) to 59.3 (SD 22.1) (p < 0.0001). The HAD score improved from 13.8 (SD 6) to 12.2 (SD 5.8) (p = 0.0032). At four months, the improvements in HFS-30 and FaCE scores were sustained (HFS-30: 35.3, SD 21; FaCE: 58.1, SD 23), while the HAD score showed no significant change from baseline (12.9, SD 5.7).
Conclusion: This study demonstrated that BoNT injection significantly enhances the quality of life of patients with unilateral facial palsy. The benefits of this improvement persisted for at least four months post-injection. Younger patients and those with shorter disease durations experienced more substantial improvements, highlighting the potential of early intervention.
Article Details
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Amar J, et al. Impact of Botulinum Toxin Injections on Quality of Life in Patients with Long-Standing Peripheral Facial Palsy. National Center for Biotechnology Information (NCBI). 2024.
ResearchGate. Impact of Botulinum Toxin Injection on the Quality of Life of Patients with Long-Standing Peripheral Facial Palsy. 2024.
Guntinas-Lichius O, et al. Botulinum Toxin for the Treatment of Facial Synkinesis, Hyperkinesis, and Hypersalivation After Facial Nerve Palsy. J Neurol Surg B Skull Base. 2017;78(1):1-7.
Dey JK, et al. The Role of Botulinum Toxin in Facial Rehabilitation Following Peripheral Facial Palsy. Plast Reconstr Surg Glob Open. 2021;9(7)
.
Laskawi R, et al. Botulinum Toxin for Treating Facial Palsy: A Review of the Literature. Facial Plast Surg. 2019;35(5):498-503.
Lim Y, et al. Quality of Life Improvements Following Botulinum Toxin Injection in Patients with Long-Standing Peripheral Facial Palsy. J Facial Plast Surg Aesthetic Med. 2020;22(6):337-344.
Carré F, et al. The Impact of Botulinum Toxin on Quality of Life in Patients with Long-Standing Peripheral Facial Palsy. Facial Plast Surg. 2020;36(6):650-657.
Finsterer J. Management of peripheral facial nerve palsy. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 2008;265(7):743-52.
Risoud M, Aljudaibi N, Duquennoy-Martinot V, Guerreschi P. Long-term sequelae treatment of peripheral facial paralysis with botulinum toxin type A: Repartition and kinetics of doses used. Annales de chirurgie plastique et esthetique. 2016;61(1):10-5.
Luijmes RE, Pouwels S, Beurskens CH, Kleiss IJ, Siemann I, Ingels KJ. Quality of life before and after different treatment modalities in peripheral facial palsy: A systematic review. The Laryngoscope. 2017;127(5):1044-51.
Azizzadeh B, Frisenda JL. Surgical Management of Postparalysis Facial Palsy and Synkinesis. Otolaryngologic clinics of North America. 2018;51(6):1169-78.
Bulnes LC, Mariën P, Vandekerckhove M, Cleeremans A. The effects of Botulinum toxin on the detection of gradual changes in facial emotion. Sci Rep. 2019;9(1):11734.
Moraleda S, Hachoue Z, Abdel-Muti E, Ruiz G, Díez Sebastián J, Lassaletta L. [Satisfaction survey of patients with sequels of peripheral facial palsy treated with botulinum toxin A]. Rehabilitacion. 2020;54(4):254-9.
de Sanctis Pecora C, Shitara D. Botulinum Toxin Type A to Improve Facial Symmetry in Facial Palsy: A Practical Guideline and Clinical Experience. Toxins. 2021;13(2).
Díaz-Aristizabal U, Valdés-Vilches M, Fernández-Ferreras TR, Calero-Muñoz E, Bienzobas-Allué E, Aguilera-Ballester L, et al. Effect of botulinum toxin typeA in functionality, synkinesis and quality of life in peripheral facial palsy sequelae. Neurologia. 2021.
Hernández Herrero D, Abdel Muti García E, López Araujo J, Alfonso Barrera E, Moraleda Pérez S. Cost of peripheral facial palsy treatment with Botulinum Toxin type A. Journal of plastic, reconstructive & aesthetic surgery : JPRAS. 2022;75(1):271-7.
de Jongh FW, Schaeffers A, Kooreman ZE, Ingels K, van Heerbeek N, Beurskens C, et al. Botulinum toxin A treatment in facial palsy synkinesis: a systematic review and meta-analysis. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 2023;280(4):1581-92.
de Jongh FW, Wolf O, Wong ZY, Ingels K, Pouwels S. Botulinum toxin treatment of the buccinator muscle facial synkinesis: A systematic review. Journal of plastic, reconstructive & aesthetic surgery : JPRAS. 2023;86:88-93.
Díaz-Aristizabal U, Valdés-Vilches M, Fernández-Ferreras TR, Calero-Muñoz E, Bienzobas-Allué E, Aguilera-Ballester L, et al. Effect of botulinum toxin type A in functionality, synkinesis and quality of life in peripheral facial palsy sequelae. Neurologia. 2023;38(8):560-5.
Amar J, Tankere F, Picard D, Alciato L, Carré F, Foirest C. Impact of Botulinum Toxin Injections on Quality of Life of Patients with Long-Standing Peripheral Facial Palsy. Toxins. 2024;16(3).
Carré F, Amar J, Tankéré F, Foirest C. Botulinum Toxin Injections to Manage Sequelae of Peripheral Facial Palsy. Toxins. 2024;16(3).